Vanquish Oncology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Phase 1
Terminated
- Conditions
- Anaplastic AstrocytomaGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Vanquish Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03332355
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins Cancer Center, Baltimore, Maryland, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Phase 1
Completed
- Conditions
- Neuroendocrine TumorsPancreatic Neuroendocrine TumorSolid Tumor
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Vanquish Oncology, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02355535
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
News
No news found